MyoKardia, Inc.
http://www.myokardia.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MyoKardia, Inc.
Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten
The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.
Gyroscope Spins Forward With Dry AMD Gene Therapy
Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.
Keeping Track: US FDA Approves J&J’s Novel MS Drug Ponvory, Breakthrough Pericarditis Claim For Kiniksa’s Arcalyst
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- ADMET
- Genomics-Proteomics